- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03347838
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-institution, open-label, single-arm, two-stage, phase II study of the PD-1 inhibitor nivolumab in patients at high risk for lung cancer. Simon's two-stage design will be used. In the first stage, 18 subjects will be enrolled. If at least 7 subjects respond to nivolumab, then an additional 24 subjects will be enrolled for a total of 42 subjects. The central hypothesis to be tested by this trial is that immune evasion contributes to malignant transformation of premalignant bronchial dysplastic lesions into invasive lung cancers, and that blocking PD-1 will allow the immune system to target and eradicate premalignant bronchial dysplastic lesions, thereby preventing the development of lung cancer.
Nivolumab 240 mg IV will be administered every two weeks for a total of four doses (8 weeks). Participants will undergo bronchoscopy with endobronchial biopsy at study entry, 2 months, and 6 months. The primary endpoint will be change in bronchial dysplasia between study entry and the 6 month timepoint. Secondary endpoints include safety and tolerability of nivolumab in patients with bronchial dysplastic lesions, and additional endobronchial histology endpoints. Exploratory endpoints will be used to identify predictive markers of response to nivolumab.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Brandi Kubala
- Phone Number: 303-724-1657
- Email: brandi.kubala@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Anschutz Medical Campus
-
Contact:
- Brandi Kubala
- Phone Number: 303-724-1657
- Email: brandi.kubala@cuanschutz.edu
-
Sub-Investigator:
- Robert Keith, M.D.
-
Denver, Colorado, United States, 80220
- Recruiting
- Denver VA Hospital
-
Contact:
- Brandi Kubala
- Phone Number: 303-724-1657
- Email: brandi.kubala@cuanschutz.edu
-
Principal Investigator:
- Robert Keith, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged > 18 years
- A current or ex-smoker with a > 30 pack-year history of smoking and mild or worse sputum cytologic atypia or known bronchial dysplasia, OR history of non-small cell lung cancer (stage I, II, or IIIA) with > 10 pack-year history of smoking and no evidence of active disease at least 1 year after definitive treatment, OR history of head and neck cancer (stage I, II, III, or IVA) with > 10 pack-year history of smoking and no evidence of active disease at least 1 year after definitive treatment. An ex-smoker is defined as no tobacco use in the prior 12 months
- Endobronchial dysplasia (score > 4) on screening bronchoscopy
- Total granulocyte count > 1500
- Platelet count > 100,000
- Serum creatinine < 1.5 mg/dL
- Total bilirubin < 2.0 mg/dL
- Transaminases and alkaline phosphatase < 2.5x upper limit of normal
- Albumin > 2.5 mg/dL
- ECOG performance status ≤ 1
- Participants must be able and willing to undergo three bronchoscopies: before, after four doses of nivolumab (8 weeks), and after 6 months
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Participants may not be currently receiving immune checkpoint inhibitor treatment or have been treated with immune checkpoint inhibitors in the past (including anti-programmed cell death receptor [PD]-1, anti-programmed death ligand 1 [PD-L1], and anti-cytotoxic T-lymphocyte associated protein 4 [CTLA4] monoclonal antibodies)
- Patients cannot receive any other investigational anti-cancer agents while participating in the study
- Participants cannot have used any other investigational agents within the previous six months
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
- Clinically apparent bleeding diathesis (i.e., bleeding that is spontaneous, excessive, or delayed in onset following tissue injury results from a localized pathologic process or a disorder of the hemostatic process, involving a complex interplay among vascular integrity, platelet number and function, coagulation factors, and fibrinolysis)
- Cardiac dysrhythmia that is potentially life-threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (< 2 minute) premature ventricular contractions are not exclusionary
- History of coronary artery disease, including myocardial infarction, congestive heart failure (LV ejection fraction <50% or clinically significant diastolic dysfunction), or any serious medical condition which would preclude a patient from undergoing a bronchoscopy or would jeopardize the goals of the study
- Individuals who are HIV-positive will be considered on a case-by-case basis, but will be required to meet criteria related to patient safety and data integrity, as assessed by the study investigators
- History of hepatitis B or hepatitis C infection that is untreated and/or with a detectable viral load
- Hypoxemia (less than 90% saturation with supplemental oxygen)
- Severe obstructive lung disease (GOLD Stage III or IV, FEV1<30% predicted)
- Prior chemotherapy or thoracic radiation within the past 1 year
- Participants with findings on CT chest suspicious for lung cancer (Lung-RADS category 4) will not be allowed to enroll until they have undergone additional evaluation for malignancy and an alternative (i.e., non-malignant) diagnosis has been established
- Current malignancy, with the exception of non-melanoma (i.e., basal cell or squamous cell) skin cancer. Patients with lung carcinoma in situ found during the study biopsy are also excluded.
- History of a malignancy except for adequately treated non-melanoma (i.e., basal cell or squamous cell) skin cancer or in situ cervical cancer for which the subject has not been disease-free for 5 years. Patients with a history of non-small cell lung cancer (stage I, II, or IIIA) or head and neck cancer (stage I, II, III, or IVA) must have no evidence of active disease at least 1 year after definitive treatment.
- History of stage IIIA NSCLC for which the only treatment was chemoradiation without surgery
- Known or suspected autoimmune disease; subjects with type I diabetes mellitus, hypothyroidism requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll
- Conditions requiring systemic corticosteroids equivalent to > 10 mg prednisone per day or other immunosuppressive medications within 2 weeks of enrollment
- Known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- History of interstitial pneumonitis requiring treatment with systemic corticosteroids or other immunosuppressive agents (e.g., mycophenolate, azathioprine)
- Life expectancy of < 1 year
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 4 weeks prior to the start of nivolumab
- Women must not be breastfeeding
- Inability to give informed consent
- Pneumonia or acute bronchitis for at least 2 weeks prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab Injection [Opdivo]
240 mg IV every 2 weeks for 4 doses
|
Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in endobronchial histology
Time Frame: 6 months
|
The primary endpoint is the dichotomous endpoint of whether a subject responds to PD-1 immune checkpoint inhibition using nivolumab.
Response will be based on the 6-month change (difference between 6-month score and baseline score) in worst (i.e., maximum) histologic classification score, using the 2004 World Health Organization (WHO) classification scale for pre-invasive squamous lesions of the bronchus.
The histologic classification consists of: normal (grade 1.0), reserve cell hyperplasia (grade 2.0), squamous metaplasia (grade 3.0), mild dysplasia (grade 4.0), moderate dysplasia (grade 5.0), severe dysplasia (grade 6.0), carcinoma in situ (grade 7.0) and invasive cancer (grade 8.0).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of immune-related adverse events (irAEs)
Time Frame: Every 2 weeks through 3 months, then every 3 months through 1 year
|
Patients will be evaluated every 2 weeks to determine whether they have any immune-related adverse events (irAEs) using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).
In particular, patients will be monitored closely for evidence of dermatological, gastrointestinal, endocrine, renal, and pulmonary irAEs.
Complete blood count, comprehensive metabolic profile, and thyroid function tests will be obtained at baseline and every 3 months for 1 year.
A comprehensive metabolic profile will also be checked every 2 weeks.
Subjects will be followed for a total of 1 year to monitor for development of irAEs after discontinuation of the study drug.
|
Every 2 weeks through 3 months, then every 3 months through 1 year
|
Additional endobronchial histology endpoints using the 2004 WHO classification scale for pre-invasive squamous lesions of the bronchus
Time Frame: 2 months and 6 months
|
|
2 months and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of T lymphocytes in bronchial dysplastic lesions that express PD-1
Time Frame: Baseline, 2 months, and 6 months
|
The proportion of T lymphocytes that express programmed death receptor 1 (PD-1) in pre- and post-treatment biopsies will be compared by immunofluorescence staining of formalin-fixed, paraffin-embedded tissue sections
|
Baseline, 2 months, and 6 months
|
Proportion of macrophages in bronchial dysplastic lesions that express PD-L1
Time Frame: Baseline, 2 months, and 6 months
|
The proportion of macrophages that express programmed death ligand 1 (PD-L1) in pre- and post-treatment biopsies will be compared by immunofluorescence staining of formalin-fixed, paraffin-embedded tissue sections
|
Baseline, 2 months, and 6 months
|
Quantification of CD4+ T lymphocyte subsets in bronchial dysplastic lesions
Time Frame: Baseline, 2 months, and 6 months
|
Pre- and post-treatment biopsies will be stained by immunofluorescence for Th1, Th2, and Treg CD4+ T lymphocytes
|
Baseline, 2 months, and 6 months
|
Ratio of M1:M2 macrophages in bronchial dysplastic lesions
Time Frame: Baseline, 2 months, and 6 months
|
Pre- and post-treatment biopsies will be stained by immunofluorescence for CD68, HLA-DRA, and CD206.
The ratio of M1 (CD68/HLA-DRA) to M2 (CD68/CD206) macrophages will be determined.
|
Baseline, 2 months, and 6 months
|
Number of non-synonymous mutations in bronchial dysplastic lesions
Time Frame: Baseline
|
The number of non-synonymous mutations in bronchial dysplastic lesions will be determined by whole exsome sequencing
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Keith, MD, University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-1492.cc
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Smoking
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
University of ArizonaNational Center for Complementary and Integrative Health (NCCIH); West Virginia...CompletedSmoking Cessation | Tobacco Use | Tobacco Smoking | Smoking, Tobacco | Guided ImageryUnited States
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedTobacco Smoking | Cigarette Smoking | Smoking, TobaccoUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco Smoking | Smoking BehaviorsUnited States
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan